AHNTI Europe exists at the heart of transformation in the animal health sector. It is where unmet needs meet bold ideas, and groundbreaking science becomes global impact.
Both companion and production animal health face mounting complexity, meaning innovation is no longer optional, it is essential. AHNTI Europe serves as the catalyst, connecting the ecosystem’s most forward-thinking players to accelerate solutions that define the future.
Over the last decade, the animal health market has tripled in value, from $55B to $143B. This explosion has been largely powered by novel technologies and therapies, particularly in companion animal therapeutics—where blockbuster products like Cytopoint and Librela now rival human treatments in sophistication and scale.
The next frontier?
- Oncology, cardiology, renal and chronic disease management in pets.
- Gene therapies, monoclonal antibodies, and CAR-T approaches adapted from human medicine.
- AI-driven drug discovery optimizing development timelines and reducing cost.
At AHNTI Europe, these are not future trends. They are active dialogues, partnerships, and launches in motion.
You'll want to be where:
- Market-defining insights are shared
- M&A and BD pipelines are actively built
- Startups get discovered, scaled and acquired
- Cross-disciplinary solutions are formed
Are you a startup ready to build your profile?
Keep your eyes peeled for the 2026 Innovation Showcase applications opening, or increase your visibility across the three days as part of the Acceleration Zone.
Are you looking to build your innovation pipeline?
Secure an enhanced presence at the show now, and make sure no startups pass you by.